Extension program for Bay 43-9006 [sorafenib].
Latest Information Update: 05 Jan 2015
Price :
$35 *
At a glance
- Drugs Sorafenib (Primary)
- Indications Cancer
- Focus Therapeutic Use
- Sponsors Bayer
- 25 Mar 2009 Actual patient number (400) added as reported by ClinicalTrials.gov.
- 06 May 2008 New trial record.